XSpray Pharma AB Asset Resilience Ratio
XSpray Pharma AB asset resilience ratio. XSpray Pharma AB (XSPRAY) has an Asset Resilience Ratio of 0.42% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See XSpray Pharma AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of XSpray Pharma AB (2022–2023)
Asset resilience ratio of XSpray Pharma AB from 2022 to 2023. This chart shows how XSpray Pharma AB's Asset Resilience Ratio has changed over time. Read XSpray Pharma AB (XSPRAY) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down XSpray Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is XSpray Pharma AB's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr3.10 Million | 0.42% |
| Total Liquid Assets | Skr3.10 Million | 0.42% |
Asset Resilience Insights
- Limited Liquidity: XSpray Pharma AB maintains only 0.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
XSpray Pharma AB Industry Peers by Asset Resilience Ratio
Compare XSpray Pharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
XSpray Pharma AB Asset Resilience Ratio by Year (2022–2023)
XSpray Pharma AB asset resilience ratio by year from 2022 to 2023. The table below shows the annual Asset Resilience Ratio data for XSpray Pharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.39% | Skr3.02 Million ≈ $324.57K |
Skr765.26 Million ≈ $82.35 Million |
+0.91pp |
| 2022-12-31 | -0.51% | Skr-3.00 Million ≈ $-322.74K |
Skr585.43 Million ≈ $63.00 Million |
-- |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more